University of Miami

Stephen C Pflugfelder

Scheffer C Tseng

Andrew J Huang

Balakrishna L Lokeshwar

Marie G Selzer

Adolfo Afonso

Scheffer C G Tseng

Kenichi Yoshino

Angelo Macri

A method for treating a patient having meibomian gland disease, ocular irritation associated with delayed tear clearance, or recurrent corneal epithelial erosion, is disclosed. Preferably, the method concerns treatment of a patient with topical tetracycline, a derivative or analogue of tetracycline, or a chemically modified tetracycline (CMT). Oral administration of a CMT is also disclosed as part of the method for treating meibomian gland disease, ocular irritation associated with delayed tear clearance, or recurrent corneal epithelial erosion.

Method for treating meibomian gland disease

A method of evaluating clearance of fluorescein dye instilled into tear film having a greater sensitivity and specificity for diagnosing a tear film disorder as the cause of a patient's ocular irritation and ocular surface disease than can be achieved using the traditional methods. The inventive method can be performed using a diagnostic kit for evaluating tear fluorescence clearance in which the concentration of tear fluorescein is visually quantified via a color standard.

Process and device for measuring tear fluorescein clearance

A preservative-free composition containing an effective amount of a corticosteroid in an aqueous carrier to treat a dry eye condition. The composition may be provided as a part of a therapeutic regimen to treat a variety of dry eye conditions and ocular surface disorders manifesting delayed tear clearance previously not readily treatable. The composition may be packaged as containers of single dosage amounts of the corticosteroid-aqueous composition sufficient for pulsed-therapy of acute exacerbations of the irritation symptoms and ocular surface disease of conditions associated with dry eye and delayed tear clearance.

Non-preserved topical corticosteroid for treatment of dry eye,

The present invention relates to medicinal compositions and more particularly refers to such compositions for tear replacement therapy having products of human lacrimal gland acinar epithelia, and more specifically, growth factors or cytokines, in particular, the transforming growth factor beta (TGF.beta.).

Growing community of inventors

Miami, FL, United States of America

Stephen C Pflugfelder